The Johns Hopkins University spinout’s latest funding will go toward further developing its lead candidate, VTA-110, for muscular dystrophy treatments.

Vita Therapeutics, a US-based cell engineering spinout of Johns Hopkins University, has secured $20m in a round led by ageing research group Cambrian Biopharma, Baltimore Business Journal has reported.
Founded in 2019, Vita is working on stem cells that can contribute to muscle regeneration in patients suffering from muscular dystrophy – a type of genetic disease that causes muscle mass to weaken progressively.
Gabsang Lee, a neurology and neuroscience associate professor at Johns Hopkins, and Kathryn Wagner, director…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
email
Linked in